Cent Eur J Public Health 2020, 28(1):65-69 | DOI: 10.21101/cejph.a5720

Epidemiological study on more accurate diagnosis of prostate cancer

Josef Kopecký1, Veronika Navláčilová2, Jana Janoutová3, Vladimír Janout3
1 Urology Department, Havířov Hospital, Havířov, Czech Republic
2 Medihope Ltd., Olomouc, Czech Republic
3 Faculty of Health Sciences, Palacký University Olomouc, Olomouc, Czech Republic

Objective: The study aimed at assessing the potential benefit of prostate health index (PHI) for early detection of prostate cancer (PCa) and the use of PHI as a marker predicting the presence of PCa before performing prostate biopsy.

Methods: The study comprised 55 males who underwent prostate biopsy. Before the procedure, blood samples were collected to test prostate specific antigen (PSA) and free/total PSA ratio (%fPSA) and PHI was calculated. Receiver operating characteristic (ROC) analysis was used to assess the benefit of these values for predicting the presence of PCa.

Results: Based on histological examination 31 males were diagnosed with PCa, the remaining 24 were negative. Among the PCa patients, 39% had a Gleason score of 6, 26% had a score of 7 and 35% had a score of 8-10. There were statistically significant differences in PHI and PSA between males with and without PCa. The areas under the ROC curve for %fPSA, total PSA and PHI were 0.712, 0.746 and 0.789, respectively. PHI showed the best predictive ability to estimate biopsy results. If the cut-off criterion PHI > 36.4 (77.42% sensitivity, 66.67% specificity) had been used, 41.7% of males would have avoided unnecessary biopsy.

Conclusion: The use of PHI may considerably improve the accuracy of PCa detection in patients with elevated PSA and thus reduce the number of unnecessary biopsies.

Klíčová slova: prostate cancer, prostate specific antigen, prostate health index, biopsy

Vloženo: 20. únor 2019; Revidováno: 17. říjen 2019; Přijato: 17. říjen 2019; Zveřejněno: 30. březen 2020  Zobrazit citaci

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kopecký J, Navláčilová V, Janoutová J, Janout V. Epidemiological study on more accurate diagnosis of prostate cancer. Cent Eur J Public Health. 2020;28(1):65-69. doi: 10.21101/cejph.a5720. PubMed PMID: 32228820.
Sdílet...
Stáhnout citaci
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Zobrazit celý článek

    Reference

    1. Epidemiology of malignant tumors in the Czech Republic [Internet]. Masaryk University [cited 2019 Oct 17]. Available from: http://www.svod.cz.
    2. Král M, Vyhnálková V, Študent V, Bouchal J. Genetic risk of prostate cancer. Ces Urol. 2010;14(3):139-47. (In Czech.)
    3. International Agency for Research on Cancer. Global Cancer Observatory [Internet]. [cited 2018 Apr 16]. Available from: https://gco.iarc.fr/.
    4. Vukovic I, Djordjevic D, Bojanic N, Babic U, Soldatovic I. Predictive value of [-2]propsa (p2psa) and its derivatives for the prostate cancer detection in the 2.0 to 10.0ng/mL PSA range. Int Braz J Urol. 2017 Jan-Feb;43(1):48-56. Přejít k původnímu zdroji... Přejít na PubMed...
    5. Wasserbauer R. Active approach to prostate cancer detection - what is reasonable and what may cause harm. Urol List. 2014;12(2):19-28. (In Czech.)
    6. Štern P, Vranovský K, Šafarčík K. Prostatic cancer - molecular basis, diagnostics and economy of prevention. Klin Biochem Metab. 2008;16(37):19-26. (In Czech.)
    7. Huang YQ, Sun T, Zhong WD, Wu CL. Clinical performance of serum [-2]proPSA derivatives, %p2PSA and PHI, in the detection and management of prostate cancer. Am J Clin Exp Urol. 2014 Dec 25;2(4):343-50.
    8. Beckman Coulter. Prostate Health Index (phi) [Internet]. Beckman Coulter [cited 2018 Apr 24]. Available from: https://www.beckmancoulter.com/products/immunoassay/phi.
    9. Loeb S, Catalona WJ. The Prostate Health Index: a new test for the detection of prostate cancer. Ther Adv Urol. 2014 Apr;6(2):74-7. Přejít k původnímu zdroji... Přejít na PubMed...
    10. Na R, Ye D, Qi J, Liu F, Helfand BT, Brendler CB, et al. Prostate health index significantly reduced unnecessary prostate biopsies in patients with PSA 2-10 ng/mL and PSA >10 ng/mL: results from a Multicenter Study in China. Prostate. 2017 Aug;77(11):1221-9. Přejít k původnímu zdroji... Přejít na PubMed...
    11. Welch HG, Albertsen PC. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. J Natl Cancer Inst. 2009 Oct 7;101(19):1325-9. Přejít k původnímu zdroji... Přejít na PubMed...
    12. Nichol MB, Wu J, An JJ, Huang J, Denham D, Frencher S, et al. Budget impact analysis of a new prostate cancer risk index for prostate cancer detection. Prostate Cancer Prostatic Dis. 2011 Sep;14(3):253-61. Přejít k původnímu zdroji... Přejít na PubMed...
    13. Nichol MB, Wu J, Huang J, Denham D, Frencher SK, Jacobsen SJ. Cost-effectiveness of Prostate Health Index for prostate cancer detection. BJU Int. 2012 Aug;110(3):353-62. Přejít k původnímu zdroji... Přejít na PubMed...
    14. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med. 2004 May 27;350(22):2239-46. Přejít k původnímu zdroji... Přejít na PubMed...
    15. Vukotic V, Cerovic S, Kozomara M, Lazic M. The predictive value of PSA in diagnosis of prostate cancer in non screened population. Acta Chir Iugosl. 2005;52(4):81-7. Přejít k původnímu zdroji... Přejít na PubMed...
    16. Tan LG, Tan YK, Tai BC, Tan KM, Gauhar V, Tiong HY, et al. Prospective validation of %p2PSA and the Prostate Health Index, in prostate cancer detection in initial prostate biopsies of Asian men, with total PSA 4-10 ng ml-1. Asian J Androl. 2017 May-Jun;19(3):286-90. Přejít k původnímu zdroji... Přejít na PubMed...
    17. Hsieh PF, Chang CH, Yang CR, Huang CP, Chen WC, Yeh CC, et al. Prostate Health Index (PHI) improves prostate cancer detection at initial biopsy in Taiwanese men with PSA 4-10 ng/mL. Kaohsiung J Med Sci. 2018 Aug;34(8):461-6. Přejít k původnímu zdroji... Přejít na PubMed...
    18. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988 Sep;44(3):837-45. Přejít k původnímu zdroji... Přejít na PubMed...

    Zpět na obsah